Audited annual filings, TTM ratios and consensus forward estimates
Wall Street price targets and rating actions
Revenue disaggregation per 10-K filing
Annual filings (FY) with consensus forward estimates (hatched)
Current price $26.37
Latest analyst grade actions
| Date | Firm | Action | Previous | New grade |
|---|---|---|---|---|
| Aug 26, 26 |
| Lake Street |
| maintain |
| Buy |
| Buy |
| May 13, 26 | B. Riley Securities | maintain | Buy | Buy |
| Feb 12, 26 | Freedom Broker | maintain | Buy | Buy |
| Nov 19, 25 | Freedom Broker | maintain | Buy | Buy |
| Nov 13, 25 | Roth Capital | maintain | Buy | Buy |
| Aug 27, 25 | Roth Capital | maintain | Buy | Buy |
| May 11, 23 | EF Hutton | maintain | Buy | Buy |
| Feb 16, 23 | EF Hutton | maintain | Buy | Buy |
| Feb 15, 23 | Lake Street | maintain | Buy | Buy |
1255 daily bars · split adjusted
Daily · Wilder smoothing
Classic floor pivots from 2026-10-23
Computed from daily OHLCV bars
| Indicator | Value | Type | Action |
|---|---|---|---|
| RSI (14) | 30.84 | Oscillator | Neutral |
| Stochastic %K (14, 3, 3) | 8.12 | Oscillator | Buy |
| Williams %R (14) | -95.81 | Oscillator | Buy |
| MACD (12, 26, 9) | -0.71 (Hist 0.06) | Oscillator | Buy |
| Average Directional Index (14) | 26.03 (+DI 11.2 / -DI 22.6) | Trend | Strong Sell |
| EMA 20 | 27.69 | MA | Strong Sell |
| SMA 20 | 27.79 | MA | Strong Sell |
| EMA 50 | 29.93 | MA | Strong Sell |
| SMA 50 | 29.74 | MA | Strong Sell |
| SMA 200 | 31.32 | MA | Strong Sell |
SEC EDGAR filings · last 12 months
| Form | Filed | Accepted | Document |
|---|---|---|---|
| DEF 14A | Sep 29, 2026 | 2026-09-29 16:17:23 | View |
| DEFA14A | Sep 29, 2026 | 2026-09-29 16:16:07 | View |
| ARS | Sep 29, 2026 | 2026-09-29 16:15:11 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:43:21 | View |
| 4 | Sep 3, 2026 | 2026-09-03 16:41:37 | View |
| 8-K | Aug 25, 2026 | 2026-08-25 16:11:57 | View |
| 10-K | Aug 25, 2026 | 2026-08-25 16:11:19 | View |
| 4 | Jul 2, 2026 | 2026-07-02 16:02:46 | View |
| 4 | Jun 9, 2026 | 2026-06-09 17:12:58 | View |
| 4 | Jun 8, 2026 | 2026-06-08 19:39:19 | View |
Proxy statement (DEF 14A) disclosures
Free float vs. closely held shares
13F institutional holdings are not available in the current data plan.
SEC Form 4 filings
| Date | Insider | Role | Type | Shares @ price | Value |
|---|---|---|---|---|---|
| Sep 1, 26 | Nagel Bradley M. | officer: Chief Financial Officer | A-Award | 4,900 | — |
| Sep 1, 26 | Nagel Bradley M. | officer: Chief Financial Officer | F-InKind | 1,102 @ $27.10 | $29.86K |
| Sep 1, 26 | Nagel Bradley M. | officer: Chief Financial Officer | A-Award | 9,600 @ $27.10 | $260.2K |
| Sep 1, 26 | Cunniff James L. | director, officer: CEO and President | F-InKind | 2,671 @ $27.10 | $72.38K |
| Jun 30, 26 | Nagel Bradley M. | officer: Chief Financial Officer | F-InKind | 674 @ $42.30 | $28.51K |
| Jun 8, 26 | Cunniff James L. | director, officer: CEO and President | M-Exempt | 9,700 @ $17.25 | $167.3K |
| Jun 8, 26 | Cunniff James L. | director, officer: CEO and President | S-Sale | 7,003 @ $36.25 | $253.9K |
| Jun 8, 26 | Cunniff James L. | director, officer: CEO and President | S-Sale | 1,671 @ $36.80 | $61.49K |
FY2024 · 10-K disclosure
FY2026 · 10-K disclosure
TTM vs. 5-year historical average (annual ratios)
| Metric | ELMD | Historical (5Y) / ref | Status |
|---|---|---|---|
| P/E ratio (TTM) | 19.2x | 28.7x · sector 20.7x | In line |
| Forward P/E (FY27E) | 18.1x | EPS est. 1.46 | In line |
| Price / Book | 4.0x | 3.6x | In line |
| Price / Sales | 3.0x | 2.7x | In line |
| EV / EBITDA | 13.0x | 17.6x | Discount |
| Return on equity | 23.4% | — | Top tier |
| Gross margin | 78.5% | 76.9% | In line |
| Debt / Equity | 0.00 | 0.00 | Conservative |
| Piotroski / Altman Z | 7/9 | Z 13.99 | Safe zone |
Discounted cash flow model
Stock news · updated daily
Cytosorbents (NASDAQ: CTSO - Get Free Report) and Electromed (NYSE: ELMD - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership and dividends. Analyst Recommendations This is a breakdown of recent ratings
Squarepoint Ops LLC acquired a new position in Electromed, Inc. (NYSE: ELMD) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 19,498 shares of the company's stock, valued at approximately $825,000. Squarepoint Ops LLC owned approximately 0.23% of Electromed as of
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. to Participate in the H.C. Wainwright 28th Annual Global Investment Conference and LD Micro 20th Annual Main Event.
Electromed's direct-to-patient model, broad payer coverage, and disciplined sales execution support durable SmartVest growth. The bronchiectasis market remains substantially underpenetrated, leaving a long runway for greater HFCWO adoption. Hospital revenue is volatile, but the channel remains small and full-year hospital sales still increased.
Electromed, Inc. (ELMD) Q4 2026 Earnings Call Transcript
Electromed, Inc. (ELMD) came out with quarterly earnings of $0.39 per share, beating the Zacks Consensus Estimate of $0.32 per share. This compares to earnings of $0.25 per share a year ago.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed Announces CEO's Planned Retirement.
NEW PRAGUE, Minn.--(BUSINESS WIRE)--Electromed, Inc. Announces Record Fiscal 2026 Fourth Quarter and Full Year Financial Results.
Reported EPS vs. consensus estimate
| Report date | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|
| Aug 25, 2026 | 0.32 | 0.39 | Beat 23.1% | $19.42M |
| May 12, 2026 | 0.26 | 0.35 | Beat 34.6% | $18.57M |
| Feb 10, 2026 | 0.27 | 0.32 | Beat 18.5% | $18.90M |
| Nov 12, 2025 | 0.22 | 0.25 | Beat 13.6% | $16.89M |
| Aug 26, 2025 | 0.22 | 0.25 | Beat 13.6% | $17.39M |
| May 13, 2025 | 0.20 | 0.21 | Beat 5.0% | $15.68M |
